Close Menu

Wellcome Sanger Institute

At a conference in Australia today, researchers from Illumina and the Wellcome Trust Sanger Institute announced that they have sequenced the Tasmanian devil genome, along with tumor genomes representing a contagious cancer decimating wild devil populations.

The recently-completed 2010 Leena Peltonen School of Human Genomics was named in honor of the Finnish geneticist and head of the Wellcome Trust Sanger Institute's human genetics program who died in March.

The UK-based firm will provide Sanger with more than 200 genetically defined cell lines with cancer-causing mutations, which will guide researchers working on the Genomics of Drug Sensitivity in Cancer project.

The collaboration will provide Horizon's X-Man cancer models to the Genomics of Drug Sensitivity in Cancer project between Sanger and the University of Massachusetts General Hospital.

So far, Illumina has shipped more than 100 HiSeq instruments for revenue, representing "the fastest instrument scale-up in the company's history for the most complex product it has ever built."

The company has expanded its early-access program to a “limited number” of sites outside North America. It previously said it is interested in having testing sites in Europe and Asia.

Paired Ends: Aug 3, 2010


Daniel Turner, Elizabeth Brady, Emily Winn-Deen, Melina Cimler, Tristan Orpin, Terry Pizzie, Ajay Bansal, John Curson, Ken Prokuski, Lewis Shuster, Stephen McLean

New Products: Aug 3, 2010



Researchers involved in the five-year Cancer Genome Project's Genomics of Drug Sensitivity study today released treatment response data on hundreds of genetically characterized cancer cell lines.

Paired Ends: Jul 13, 2010


Harold Varmus, Gerald Möller, Harold Swerdlow, Gary King


The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.